Optimal tactics of ovarian and metachronous breast cancer treatment in BRCA mutations carriers
Open Access
- 7 December 2023
- journal article
- research article
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 28-34
Abstract
Treatment of patients with multiple primary malignant neoplasms caused by genetic mutations requires correct priorities from the clinician in selection of the most effective therapeutic tactics. An important aspect in this case is the identification of the neoplasm determining patient’s survival. The main goal is to achieve maximal treatment effect for this tumor and use therapy methods for control of other synchronous and metachronous tumors.The article presents a clinical case of a patient with BRCA1 mutation-associated recurrent ovarian cancer and de novo breast cancer of negative subtype. Combination multidisciplinary and personalized approach to treatment which led to the maximally effective result is described. Personalized approach to prescription of antitumor drug therapy, timing of surgical intervention and subsequent targeted therapy allowed to realize maximal antitumor effect and increase the patient’s lifespan.Keywords
This publication has 15 references indexed in Scilit:
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and PreventionScience, 2014
- Prophylactic mastectomy for the prevention of breast cancerCochrane Database of Systematic Reviews, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2010
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2MutationNew England Journal of Medicine, 2002
- Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2MutationsNew England Journal of Medicine, 2002